Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Serotonin and norepinephrine reuptake inhibitor antidepressants: a look through the prism of their 30-year history

https://doi.org/10.14412/2074-2711-2018-4-4-12

Full Text:

Abstract

Based on the data available in the literature, the author has first systematized in detail the main stages of the design and clinical introduction of serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressants. Theoretical prerequisites for their emergence are described. The evaluation of the efficiency of depression therapy with drugs of this group in clinical trials and post-marketing studies is analyzed in the historical context. The reasons for temporary restrictions on their wide use are considered. There are data on the design of novel representatives of SNRI antidepressants.

About the Author

D. S. Danilov
S.S. Korsakov Clinic of Psychiatry; University Clinical Hospital Three, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation

Dmitry Sergeevich Danilov

Moscow, 11, Rossolimo St., Build. 9, Moscow 119021



References

1. Claassen V, Boschman TA, Dhasmana KM, et al. Pharmacology of clovoxamine, a new non-tricyclic antidepressant. Arzneimittel-forschung. 1978;28(10):1756-66.

2. De Bree H. Gas chromatographic determination of clovoxamine fumarate (DU 23811) in plasma. Unpublished Report no. 56630/30Philips-Duphar B.V. 1976 b.

3. Van Praag HM. Studies in the mechanism of action of serotonin precursors in depression. Psychopharmacol Bull. 1984 Summer;20(3): 599-602.

4. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993 Jan;8(1):23-33.

5. Scott G, Luscombe GP, Mason R. The effects of BTS 54,505, a metabolite of sibutramine, on monoamine and excitatory amino acid-evoked responses in the rat dorsolateral geniculate nucleus in vivo. Br J Pharmacol. 1994 Jan; 111(1):97-102.

6. Von Frenckell R, Ansseau M, Serre C, Sutet P. Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. Int Clin Psychopharmacol.

7. Leinonen E, Lepola U, Koponen H, et al. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand. 1997 Dec;96(6):497-504.

8. Ansseau M, von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology (Berl). 1989;98(2):163-8.

9. Ansseau M, Von Frenckell R, Gcard MA, et al. Interest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxam-ine. Eur Neuropsychopharmacol. 1991 May;1(2): 113-21.

10. Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl). 1994 Feb;114(1):131-7.

11. Lopez-Ibor J, Guelfi JD, Pletan Y, et al. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:41-6.

12. Milnacipran: new preparation. Tricyclics remain first-line antidepressants. Prescrire Int. 1998 Apr;7(34):51-3.

13. Nakagawa A, Watanabe N, Omori IM, et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006529. doi: 10.1002/14651858.CD006529.pub2.

14. Auclair AL, Martel JC, Assia MB, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013 Jul;70:338-47. doi: 10.1016/j.neuro-pharm.2013.02.024. Epub 2013 Mar 13.

15. Avedisova AS, Aleksand-rovskii YuA, Il'ina NA, et al. Ixel (milnacipran): summarized the results of a clinical study of a selective reuptake inhibitor of serotonin and norepinephrine (CISSN) in Russia. Psikhiatriya i psikho-farmakoterapiya. 2000;2(4):111-4. (In Russ.).

16. Muzychenko AP, Morozov PV, Kargal'tsev DA, Tsypin DL. Ixel in clinical practice. Psikhiatriya ipsikhofar-makoterapiya. 2000;2(3):81-5. (In Russ.).

17. Avedisova AS. Venlafaxine (velaxin): the results of international studies of antidepressant of III generation. Psikhiatriya i psikhofarmakoterapiya. 2006;8(2):33-8. (In Russ.).

18. Ivanov MV, Banshchikov FR, Kil'deev VV. Experience of application efevel-one in the treatment of anxiety and depressive disorders. Psikhiatriya i psikhofarmakoterapiya. 2006;8(6):24-7. (In Russ.).

19. Krasnov VN, Kryukov VV. Velaxin (venlafaxin) in modern depression therapy: results of the first Russian multicenter efficacy and safety study. Psikhiatriya i psikhofarmakoterapiya. 2007; 9(4):29-32. (In Russ.).

20. Vertogradova OP, Moiseicheva OV. Features of the dynamics of depression in the treatment with simbalta. Sotsial'naya i klinicheskayapsikhiatriya. 2009; 19(4):42-6. (In Russ.).

21. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol. 2007 Aug;64(2): 192-7. Epub 2007 Feb 12.

22. Martinez C, Assimes TL, Mines D, et al. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ. 2010 Feb 5;340:c249. doi: 10.1136/bmj.c249.

23. Isbister GK. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol. 2009 May;67(5):572-6. doi: 10.1111/j.1365-2125.2009.03382.x. Epub 2009 Feb 2.

24. Taylor D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol. 2013 Jun;3(3):151-61. doi: 10.1177/2045125312472890.

25. Lessing C, Ashton T, Davis P. An Evaluation of health service impacts consequent to switching from brand to generic venlafaxine in New Zealand under conditions of price neutrality. Value Health. 2015 Jul;18(5):646-54. doi: 10.1016/j.jval.2015.02.020. Epub 2015 Jul 22.

26. Rubino A, Roskell N, Tennis P, et al. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ. 2007 Feb 3;334(7587): 242. Epub 2006 Dec 12.

27. Chan AN, Gunja N, Ryan CJ. A comparison of venlafaxine and SSRIs in deliberate selfpoisoning. J Med Toxicol. 2010 Jun;6(2):116-21. doi: 10.1007/s13181-010-0013-x.

28. Avedisova A, Borodin V, Zakharova K, Aldushin A. Effect of milnacipran on suicidality in patients with mild to moderate depressive disorder. Neuropsychiatr Dis Treat. 2009;5: 415-20. Epub 2009 Aug 20.

29. Courtet P. Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran. Neuropsychiatr Dis Treat. 2010 Sep 7;6:3-8. doi: 10.2147/NDT.S11774.

30. Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol. 2006 Dec; 26(6):587-94.

31. Delini-Stula A. Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake. Hum Psychopharmacol. 2000 Jun;15(4):255-260.

32. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing milnacipran, a serotonin-norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2007 Jan;17(1):32-6. Epub 2006 Jun 8.

33. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafax-ine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001 Mar;178:234-41.

34. Kavirajan H. Venlafaxine and SSRI remission data revisited. Br J Psychiatry. 2004 May; 184:452-3.

35. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci. 2006 Mar;31(2):122-31.

36. Drobizhev MYu. Selective serotonin and noradrenaline reuptake inhibitors. More differences than similarities. Psikhiatriya i psikho-farmakoterapiya. 2005;7(4):217-23. (In Russ.).

37. Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533. doi: 10.1002/14651858.CD006533.pub2.

38. Puech A, Montgomery SA, Prost JF, et al. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol. 1997 Mar;12(2):99-108.

39. Cipriani A, Signoretti A, Furukawa TA, et al. Venlafaxine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2007;(2). pii: CD006530.

40. Panteleeva GP, Oleichik IV, Abramova LI, Yumatova PE. Treatment of endogenous depression with venlafaxine: clinical effect, tolerability and personalized indications. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(2)43-51. (In Russ.).

41. Healy D, McMonagle T. The enhancement of social functioning as a therapeutic principle in the management of depression. J Psychopharmacol. 1997;11(4 Suppl):S25-31.

42. Cloninger CR. A unified biosocial theory of personality and its role in the development of anxiety states. Psychiatr Dev. 1986 Autumn;4(3): 167-226.

43. Van Praag H. Make-believes in psychiatry or the perils of progress (1st edition). New York: Brunner/Mazel Publishers; 1992. 320 p.

44. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69 Suppl E1:4-7.

45. ОЦе JP, Gourion D, Montagne A, et al. Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, doubleblind exploratory study. Neuropsychiatr Dis Treat. 2010 Apr 7;6:71-9.

46. Mansuy L. Antidepressant therapy with milnacipran and venlafaxine. Neuropsychiatric Disease Treatment. 2010;6(Suppl 1):17-22.

47. Wang CP, Howell SR, Scatina J, Sisenwine SF. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality. 1992;4(2):84-90.

48. Muth FA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological and behavioral effects of WY 45, 233, it's enantiomers, and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991;23:191-9.

49. Poitras V, Visintini S. Desvenlafaxine versus venlafaxine for the treatment of adult patients with major depressive disorder: a review of the comparative clinical and cost-effectiveness. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017.

50. Lourenco MT, Kennedy SH. Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2009;5:127-36. Epub 2009 Apr 8.


For citation:


Danilov D.S. Serotonin and norepinephrine reuptake inhibitor antidepressants: a look through the prism of their 30-year history. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):4-12. (In Russ.) https://doi.org/10.14412/2074-2711-2018-4-4-12

Views: 922


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)